TITLE

Is it time to retire niacin?

PUB. DATE
January 2012
SOURCE
OB/GYN Clinical Alert;Jan2012 Pharmacology, p2
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on several factors and evidences which suggest that the continued use of drug niacin should be discarded, including its inefficacy in supporting the intensive statin therapy used for curing cardiovascular disease, its high cost and frequent incidences of flushing due to its intake.
ACCESSION #
74206390

 

Related Articles

  • Niacin: old habits die hard. Haynes, Richard; Rahimi, Kazem // Heart;Feb2016, Vol. 102 Issue 3, p170 

    The authors reflect on the use of the vitamin niacin in the treatment of cardiovascular diseases. Topics discussed include the factors which influence the risk of cardiovascular disease in patients, the authors' assessment of the studies investigating the impact of niacin in the treatment of...

  • Journal of Clinical Investigation: Penn study cautions use of drugs to block 'niacin flush'.  // Biomedical Market Newsletter;4/14/2012, Vol. 21, p1 

    The article informs that the researchers from the University of Pennsylvania caution the use of receptor blocking drugs in cardiovascular patients taking niacin.

  • American Heart Association.  // BioWorld Today;11/17/2009, Vol. 20 Issue 222, p9 

    This article focuses on a study by Abbott which found that patients at high cardiovascular risk had significant regression of atherosclerosis after several months of therapy with its Niaspan, or niacin extended-release tablets, plus a statin. According to the study, Niaspan plus statin also led...

  • Nateglinide does not reduce CV events in patients with impaired glucose tolerance.  // JAAPA: Journal of the American Academy of Physician Assistants (;Jun2010, Vol. 23 Issue 6, p54 

    The article reports on a study which found that nateglinide does not prevent cardiovascular (CV) events in patients with impaired glucose tolerance.

  • Drugs Used to Manage Cardiovascular Disease Part I--Diuretics. Spolarich, Ann Eshenaur // Access;Feb2001, Vol. 15 Issue 2, p30 

    Part I. Focuses on efficacy of medications in treating cardiovascular conditions in the United States. Identification of thiazide as most widely used drugs; Accounts on loop and potassium-sparing diuretics; Accounts on the cardiac conditions treated with the drug; Clinical manifestation of...

  • Adverse cardiovascular response to oral trimeprazine in children. Loan, W.H.; Cuthbert, D. // British Medical Journal (Clinical Research Edition);5/25/1985, Vol. 290 Issue 6481, p1548 

    Examines the adverse cardiovascular response to oral trimeprazine in children. Utilization of trimeprazine as premedicant and general pediatric sedative; Absence of hypotensive complications; Factors arising from preanesthetic sedatives.

  • A Review of Niaspan, an Extended-Release Niacin. Abourjaily, Heather M. // Nutrition in Clinical Care;Sep/Oct2001, Vol. 4 Issue 5, p250 

    Abstract Niacin is an effective lipid-lowering therapy that has been available for more than 40 years. Many studies have proven niacin's effectiveness in decreasing morbidity and mortality and improving the entire lipid profile. However, one of the major drawbacks to niacin therapy has been its...

  • Ask This Question Before Taking Statins. Penberthy, W. Todd // Positive Health;Feb2014, Issue 212, p1 

    The article addresses a question regarding the early death of individuals with cardiovascular disease. It mentions the causes of cardiovascular disease, the role of diet in the development of this disease and the importance of essential nutrients, such as statins, in preventing cardiovascular...

  • Niacin and Atherosclerotic Cardiovascular Disease. Sadovsky, Richard // American Family Physician;4/1/1999, Vol. 59 Issue 7, p1959 

    Presents an abstract of the study `Effect of niacin on atherosclerotic cardiovascular disease,' by J.R. Guyton, from the `American Journal of Cardiology' dated December 17, 1998.

  • Cardiovascular Outcomes in the Irbesartan Diabetic Nephropathy Trial of Patients with Type 2 Diabetes and Overt Nephropathy. Berl, Tomas; Hunsicker, Lawrence G.; Lewis, Julia B.; Pfeffer, Marc A.; Porush, Jerome G.; Rouleau, Jean-Lucien; Drury, Paul L.; Esmatjes, Enric; Hricik, Donald; Parikh, Chirag R.; Raz, Itamar; Vanhille, Philippe; Wiegmann, Thomas B.; Wolfe, Bernard M.; Locatelli, Francesco; Goldhaber, Samuel Z.; Lewis, Edmund J. // Annals of Internal Medicine;4/1/2003, Vol. 138 Issue 7, p542 

    Compares rates of cardiovascular events among patients with type 2 diabetic nephropathy who received antihypertensive therapy with an angiotensin-receptor blocker or a calcium-channel blocker or placebo. Randomized placebo-controlled trial of participants; Measurement of time to cardiovascular...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics